Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 174


Roles of nonhomologous end-joining pathways in surviving topoisomerase II-mediated DNA damage.

Malik M, Nitiss KC, Enriquez-Rios V, Nitiss JL.

Mol Cancer Ther. 2006 Jun;5(6):1405-14.


Tyrosyl-DNA phosphodiesterase (Tdp1) participates in the repair of Top2-mediated DNA damage.

Nitiss KC, Malik M, He X, White SW, Nitiss JL.

Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):8953-8. Epub 2006 Jun 2.


Genetic evidence for involvement of two distinct nonhomologous end-joining pathways in repair of topoisomerase II-mediated DNA damage.

Adachi N, Iiizumi S, So S, Koyama H.

Biochem Biophys Res Commun. 2004 Jun 11;318(4):856-61.


Isolation and characterization of mAMSA-hypersensitive mutants. Cytotoxicity of Top2 covalent complexes containing DNA single strand breaks.

Rogojina AT, Nitiss JL.

J Biol Chem. 2008 Oct 24;283(43):29239-50. doi: 10.1074/jbc.M804058200. Epub 2008 Aug 22.


Yeast recombination pathways triggered by topoisomerase II-mediated DNA breaks.

Sabourin M, Nitiss JL, Nitiss KC, Tatebayashi K, Ikeda H, Osheroff N.

Nucleic Acids Res. 2003 Aug 1;31(15):4373-84.


Evidence for a role of vertebrate Rad52 in the repair of topoisomerase II-mediated DNA damage.

Adachi N, Iiizumi S, Koyama H.

DNA Cell Biol. 2005 Jun;24(6):388-93.


Amsacrine and etoposide hypersensitivity of yeast cells overexpressing DNA topoisomerase II.

Nitiss JL, Liu YX, Harbury P, Jannatipour M, Wasserman R, Wang JC.

Cancer Res. 1992 Aug 15;52(16):4467-72.


Topoisomerase II-mediated DNA damage is differently repaired during the cell cycle by non-homologous end joining and homologous recombination.

de Campos-Nebel M, Larripa I, González-Cid M.

PLoS One. 2010 Sep 2;5(9). pii: e12541. doi: 10.1371/journal.pone.0012541.


Differential and common DNA repair pathways for topoisomerase I- and II-targeted drugs in a genetic DT40 repair cell screen panel.

Maede Y, Shimizu H, Fukushima T, Kogame T, Nakamura T, Miki T, Takeda S, Pommier Y, Murai J.

Mol Cancer Ther. 2014 Jan;13(1):214-20. doi: 10.1158/1535-7163.MCT-13-0551. Epub 2013 Oct 15.


Mms22p protects Saccharomyces cerevisiae from DNA damage induced by topoisomerase II.

Baldwin EL, Berger AC, Corbett AH, Osheroff N.

Nucleic Acids Res. 2005 Feb 17;33(3):1021-30. Print 2005.


The top2-5 mutant of yeast topoisomerase II encodes an enzyme resistant to etoposide and amsacrine.

Jannatipour M, Liu YX, Nitiss JL.

J Biol Chem. 1993 Sep 5;268(25):18586-92.


DNA topoisomerase-targeting antitumor drugs can be studied in yeast.

Nitiss J, Wang JC.

Proc Natl Acad Sci U S A. 1988 Oct;85(20):7501-5.


NK314, a topoisomerase II inhibitor that specifically targets the alpha isoform.

Toyoda E, Kagaya S, Cowell IG, Kurosawa A, Kamoshita K, Nishikawa K, Iiizumi S, Koyama H, Austin CA, Adachi N.

J Biol Chem. 2008 Aug 29;283(35):23711-20. doi: 10.1074/jbc.M803936200. Epub 2008 Jul 2.


DNA double-strand break repair pathways and cellular tolerance to inhibitors of topoisomerase II.

Caldecott K, Banks G, Jeggo P.

Cancer Res. 1990 Sep 15;50(18):5778-83.

Supplemental Content

Support Center